Key result
Alirocumab cuts stroke risk ~28% in recent ACS without increasing hemorrhagic stroke.
Why the study?
Lowering atherogenic lipoproteins reduces ischemic stroke risk, but concerns exist about very low LDL-C levels increasing hemorrhagic stroke risk, necessitating evaluation of alirocumab's effect on stroke outcomes.
Does alirocumab reduce the risk of ischemic and hemorrhagic stroke in patients with recent acute coronary syndrome and elevated atherogenic lipoproteins despite intensive statin therapy?
RCT (n=18,924)
randomized
Does alirocumab reduce the risk of ischemic and hemorrhagic stroke in patients with recent acute coronary syndrome and elevated atherogenic lipoproteins despite intensive statin therapy?
In patients with recent ACS on intensive statin therapy, alirocumab significantly reduced the risk of stroke, including ischemic stroke, without increasing the risk of hemorrhagic stroke, regardless of baseline LDL-C or prior cerebrovascular disease.
Answers are grounded in this paper and cite their sources.
No increased hemorrhagic stroke with alirocumab at LDL-C 25-50 mg/dL; leaves open risks at sustained lower levels or in other populations.
Background: Lowering of atherogenic lipoproteins, including low-density lipoprotein cholesterol (LDL-C), reduces the risk of ischemic stroke. However, concerns have been raised about very low LDL-C levels and a potential increased risk of hemorrhagic stroke. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome and elevated atherogenic lipoproteins, despite intensive statin therapy, targeting LDL-C levels of 25 to 50 mg/dL and avoiding sustained LDL-C <15 mg/dL. This prespecified analysis was designed to assess the effect of alirocumab on ischemic and hemorrhagic stroke. We hypothesized that for patients treated with alirocumab there would be a reduction in risk of ischemic stroke without increasing hemorrhagic stroke, irrespective of baseline LDL-C and of history of cerebrovascular disease. Methods: Patients were randomized to alirocumab or placebo 1 to 12 months after acute coronary syndrome. The risk of nonfatal or fatal ischemic or hemorrhagic stroke was evaluated, stratified by baseline LDL-C concentration and history of cerebrovascular disease. A potential association of very low achieved LDL-C with alirocumab treatment at month 4 and subsequent hemorrhagic stroke was assessed. Results: Median follow-up was 2.8 years. In total, 263 ischemic and 33 hemorrhagic strokes occurred. Alirocumab reduced the risk of any stroke (HR, 0.72 [95% CI, 0.57−0.91]) and ischemic stroke (HR, 0.73 [95% CI, 0.57−0.93]) without increasing hemorrhagic stroke (HR, 0.83 [95% CI, 0.42−1.65]). In total, 7164 (37.9%), 6128 (32.4%), and 5629 (29.7%) patients had a baseline LDL-C of <80, 80 to 100, and >100 mg/dL, respectively. The treatment effect on stroke appeared numerically greater for patients with higher baseline LDL-C, but there was no formal evidence of heterogeneity ( P interaction =0.31). The effect of alirocumab on stroke was similar among 944 patients (5.0%) with a history of previous cerebrovascular disease and among those without a history of cerebrovascular disease ( P interaction =0.37). There was no apparent adverse relation between lower achieved LDL-C and incidence of hemorrhagic stroke in the alirocumab group. Conclusions: In patients with recent acute coronary syndrome and dyslipidemia despite intensive statin therapy, alirocumab decreased the risk of stroke, irrespective of baseline LDL-C and history of cerebrovascular disease, over a median follow-up of 2.8 years. Furthermore, risk of hemorrhagic stroke did not depend on achieved LDL-C levels within the alirocumab group. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01663402.
No takes yet. Share an insight, caveat, or question.
Jukema et al. (2019) conducted an RCT in recent acute coronary syndrome and elevated atherogenic lipoproteins (n=18,924). Alirocumab vs. placebo was evaluated on any stroke (HR 0.72, 95% CI 0.57-0.91). Alirocumab reduced the risk of any stroke and ischemic stroke without increasing hemorrhagic stroke in patients with recent ACS.
Synapse has enriched 10 related papers. Consider them for comparative context: